Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05489783 · ClinicalTrials.gov registry record
Glioma Developmental and HyperActive Ras Tumor (DHART) Board
A clinical trial of Glioma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 50
- Enrollment target
- 7
- Study locations
NCT05489783 is a study of Glioma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 50 participants, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (76% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT05489783, a study of Glioma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will collect medical records, scan results, and complete surveys to create a registry about people with a neurofibromatosis type 1-associated brain tumor (NF1-associated glioma). A registry is a collection of health information about individuals, and it is usually focused on a specific diagnosis or condition. This registry study will help the researchers learn more about the diagnosis, treatment, and quality of life of people with NF1-associated glioma. The researchers want to understand what happens as a result of different treatments for NF1-associated glioma and how these treatments and the disease itself affect people's lives over a period of time. Information collected during this study could affect how doctors diagnose, test, and treat NF1-associated glioma, and the study could help future patients with this type of cancer.
Conditions Studied
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering West Harrison (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-07-29 |
| Est. Completion | 2026-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05489783
The ClinicalTrials.gov registry entry for NCT05489783 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (76% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 0 interventions.
NCT05489783 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05489783 about?
NCT05489783 is a clinical study titled "Glioma Developmental and HyperActive Ras Tumor (DHART) Board". This study will collect medical records, scan results, and complete surveys to create a registry about people with a neurofibromatosis type 1-associated brain tumor (NF1-associated glioma). A registry is a collection of health information about individuals, and it is usually focused on a specific di...
What is the current status of trial NCT05489783?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2022-07-29. Estimated completion is 2026-07-31.
What conditions does trial NCT05489783 study?
This clinical trial studies the following conditions: Glioma.
Who is sponsoring clinical trial NCT05489783?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05489783 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks
RECRUITING
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.